ArticleBiomaterials2009
Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.
Article in Biomaterials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cell penetrating peptide-functionalized small interfering RNA nanoparticles knock down HER expression in breast cancer cells.The Journal of pharmacology and experimental therapeutics · 2025Article
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Enhancing RNA Payload and Temperature Stability and Activity with Cationic Peptide-Coated Zinc Oxide Nanoparticles.ACS pharmacology & translational science · 2024Article
- Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: a review.Biotechnology letters · 2023Review
- Spectrophotometric and nucleic acid-binding properties of halloysite clay nanotubes and kaolinite.Heliyon · 2023Article
- Comparative Molecular Immunological Activity of Physiological Metal Oxide Nanoparticle and its Anticancer Peptide and RNA Complexes.Nanomaterials (Basel, Switzerland) · 2019Article
- Translating Nanomedicine to Comparative Oncology-the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer.The Journal of pharmacology and experimental therapeutics · 2019Review
- Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines.Drug delivery · 2018Review
- Protamine-stabilized gold nanoclusters as a fluorescent nanoprobe for lead(II) via Pb(II)-Au(I) interaction.Mikrochimica acta · 2018Article
- Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy.Pharmaceutical research · 2014Article
- Gold nanoparticle mediated cancer immunotherapy.Nanomedicine : nanotechnology, biology, and medicine · 2014Review
- mPEG-PAMAM-G4 nucleic acid nanocomplexes: enhanced stability, RNase protection, and activity of splice switching oligomer and poly I:C RNA.Biomacromolecules · 2013Article
- Article
- Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy.BioImpacts : BI · 2013Article
- Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference.Nanomedicine (London, England) · 2012Article
- Association of poly I:C RNA and plasmid DNA onto MnO nanorods mediated by PAMAM.Langmuir : the ACS journal of surfaces and colloids · 2012Article
- Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules.Nanotechnology, science and applications · 2010Review
- Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Macromolecular nucleic acids such as DNA vaccines, siRNA, and splice-site switching oligomers (SSO) have vast chemotherapeutic potential. Nanoparticulate biomaterials hold promise for DNA and RNA delivery when a means for binding is identified that retains structure-function and provides stabilization by the nanoparticles. In order to provide these benefits of binding, we combined DNA and RNA with protamine-demonstrating association to gold microparticles by electrophoretic, gel shot, fluorescence, and dynamic laser light spectroscopy (DLLS). A pivotal finding in these studies is that the Au-protamine-DNA conjugates greatly stabilize the DNA; and DNA structure and vaccine activity are maintained even after exposure to physical, chemical, and temperature-accelerated degradation. Specifically, protamine formed nanoparticles when complexed to RNA. These complexes could be detected by gel shift and were probed by high throughput absorbance difference spectroscopy (HTADS). Biological activity of these RNA nanoparticles (RNPs) was demonstrated also by a human tumor cell splice-site switching assay and by siRNA delivery against B-Raf-a key cancer target. Finally, RNA:protamine particles inhibited growth of cultured human tumor cells and bacteria. These data provide new insights into DNA and RNA nanoparticles and prospects for their delivery and chemotherapeutic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.